BioWorld

Nov. 23, 2009

SPAs on the Rise for Many, Despite Setbacks for a Few

Twice this month, biotechs that achieved their primary endpoints in a pivotal trial conducted under a special protocol assessment (SPA) found their drugs turned down by the FDA. Read More

Of Vivus and Viagra: Could Patent Expiry Rattle ED Bid?

Money Raised Year to Date

Money Raised By Biotech in 2009

Week in Review

Word on the Street

Biotechnology Company Deals With Other Biotechnology Companies: October 1 - November 19, 2009

Manufacturing, Marketing And Distribution Agreements Between Biotech Companies: October 1 - November 19, 2009

Biotech - Biotech Collaborations: Modified Agreements: October 1 - November 19, 2009

Stock Gainers and Losers For The Week

BioWorld Stock Report For Public Biotechnology Companies

Today's news in brief

BioWorld

BioWorld briefs for March 19, 2026.

Precision psychiatry beyond, or before, biomarkers

BioWorld

There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...

Keros reports beneficial effects of RKER-065 in ALS model

BioWorld Science

Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.

News in brief

BioWorld Asia

BioWorld Asia briefs for March 17, 2026

First-in-class POLG activator restores mtDNA across mutations

BioWorld Science

Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...